Evidence-based review of data on the combination inhaler umeclidinium/vilanterol in patients with COPD

Timothy E Albertson, Willis S. Bowman, Richart W Harper, Regina M. Godbout, Susan Murin

Research output: Contribution to journalReview article

Abstract

The use of inhaled, fixed-dose, long-acting muscarinic antagonists (LAMA) combined with long-acting, beta2-adrenergic receptor agonists (LABA) has become a mainstay in the maintenance treatment of chronic obstructive pulmonary disease (COPD). One of the fixed-dose LAMA/LABA combinations is the dry powder inhaler (DPI) of umeclidinium bromide (UMEC) and vilanterol trifenatate (VI) (62.5 µg/25 µg) approved for once-a-day maintenance treatment of COPD. This paper reviews the use of fixed-dose combination LAMA/LABA agents focusing on the UMEC/VI DPI inhaler in the maintenance treatment of COPD. The fixed-dose combination LAMA/LABA inhaler offers a step beyond a single inhaled maintenance agent but is still a single device for the COPD patient having frequent COPD exacerbations and persistent symptoms not well controlled on one agent. Currently available clinical trials suggest that the once-a-day DPI of UMEC/VI is well-tolerated, safe and non-inferior or better than other currently available inhaled fixed-dose LAMA/LABA combinations for COPD.

Original languageEnglish (US)
Pages (from-to)1251-1265
Number of pages15
JournalInternational journal of chronic obstructive pulmonary disease
Volume14
DOIs
StatePublished - Jan 1 2019

Fingerprint

Nebulizers and Vaporizers
Adrenergic Agonists
Muscarinic Antagonists
Chronic Obstructive Pulmonary Disease
Dry Powder Inhalers
Bromides
Disease Progression
GSK573719
vilanterol
Therapeutics
Maintenance
Clinical Trials
Equipment and Supplies

Keywords

  • COPD
  • fixed-dose combination inhalers
  • LABA
  • LAMA
  • long-acting beta2-adrenergic agonists
  • long-acting muscarinic antagonists
  • umeclidinium bromide
  • vilanterol trifenatate

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Health Policy
  • Public Health, Environmental and Occupational Health

Cite this

@article{f9e0ffc75880471a888b7907bd50e56e,
title = "Evidence-based review of data on the combination inhaler umeclidinium/vilanterol in patients with COPD",
abstract = "The use of inhaled, fixed-dose, long-acting muscarinic antagonists (LAMA) combined with long-acting, beta2-adrenergic receptor agonists (LABA) has become a mainstay in the maintenance treatment of chronic obstructive pulmonary disease (COPD). One of the fixed-dose LAMA/LABA combinations is the dry powder inhaler (DPI) of umeclidinium bromide (UMEC) and vilanterol trifenatate (VI) (62.5 µg/25 µg) approved for once-a-day maintenance treatment of COPD. This paper reviews the use of fixed-dose combination LAMA/LABA agents focusing on the UMEC/VI DPI inhaler in the maintenance treatment of COPD. The fixed-dose combination LAMA/LABA inhaler offers a step beyond a single inhaled maintenance agent but is still a single device for the COPD patient having frequent COPD exacerbations and persistent symptoms not well controlled on one agent. Currently available clinical trials suggest that the once-a-day DPI of UMEC/VI is well-tolerated, safe and non-inferior or better than other currently available inhaled fixed-dose LAMA/LABA combinations for COPD.",
keywords = "COPD, fixed-dose combination inhalers, LABA, LAMA, long-acting beta2-adrenergic agonists, long-acting muscarinic antagonists, umeclidinium bromide, vilanterol trifenatate",
author = "Albertson, {Timothy E} and Bowman, {Willis S.} and Harper, {Richart W} and Godbout, {Regina M.} and Susan Murin",
year = "2019",
month = "1",
day = "1",
doi = "10.2147/COPD.S191845",
language = "English (US)",
volume = "14",
pages = "1251--1265",
journal = "International Journal of COPD",
issn = "1176-9106",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Evidence-based review of data on the combination inhaler umeclidinium/vilanterol in patients with COPD

AU - Albertson, Timothy E

AU - Bowman, Willis S.

AU - Harper, Richart W

AU - Godbout, Regina M.

AU - Murin, Susan

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The use of inhaled, fixed-dose, long-acting muscarinic antagonists (LAMA) combined with long-acting, beta2-adrenergic receptor agonists (LABA) has become a mainstay in the maintenance treatment of chronic obstructive pulmonary disease (COPD). One of the fixed-dose LAMA/LABA combinations is the dry powder inhaler (DPI) of umeclidinium bromide (UMEC) and vilanterol trifenatate (VI) (62.5 µg/25 µg) approved for once-a-day maintenance treatment of COPD. This paper reviews the use of fixed-dose combination LAMA/LABA agents focusing on the UMEC/VI DPI inhaler in the maintenance treatment of COPD. The fixed-dose combination LAMA/LABA inhaler offers a step beyond a single inhaled maintenance agent but is still a single device for the COPD patient having frequent COPD exacerbations and persistent symptoms not well controlled on one agent. Currently available clinical trials suggest that the once-a-day DPI of UMEC/VI is well-tolerated, safe and non-inferior or better than other currently available inhaled fixed-dose LAMA/LABA combinations for COPD.

AB - The use of inhaled, fixed-dose, long-acting muscarinic antagonists (LAMA) combined with long-acting, beta2-adrenergic receptor agonists (LABA) has become a mainstay in the maintenance treatment of chronic obstructive pulmonary disease (COPD). One of the fixed-dose LAMA/LABA combinations is the dry powder inhaler (DPI) of umeclidinium bromide (UMEC) and vilanterol trifenatate (VI) (62.5 µg/25 µg) approved for once-a-day maintenance treatment of COPD. This paper reviews the use of fixed-dose combination LAMA/LABA agents focusing on the UMEC/VI DPI inhaler in the maintenance treatment of COPD. The fixed-dose combination LAMA/LABA inhaler offers a step beyond a single inhaled maintenance agent but is still a single device for the COPD patient having frequent COPD exacerbations and persistent symptoms not well controlled on one agent. Currently available clinical trials suggest that the once-a-day DPI of UMEC/VI is well-tolerated, safe and non-inferior or better than other currently available inhaled fixed-dose LAMA/LABA combinations for COPD.

KW - COPD

KW - fixed-dose combination inhalers

KW - LABA

KW - LAMA

KW - long-acting beta2-adrenergic agonists

KW - long-acting muscarinic antagonists

KW - umeclidinium bromide

KW - vilanterol trifenatate

UR - http://www.scopus.com/inward/record.url?scp=85068874913&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068874913&partnerID=8YFLogxK

U2 - 10.2147/COPD.S191845

DO - 10.2147/COPD.S191845

M3 - Review article

VL - 14

SP - 1251

EP - 1265

JO - International Journal of COPD

JF - International Journal of COPD

SN - 1176-9106

ER -